 Precision BioSciences Inc NASDAQ: DTIL and SpringWorks Therapeutics Inc NASDAQ: SWTX have dosed the first patient in the combination arm of Precisions Phase 12a trial evaluating PBCAR269A. In the study, Precisions investigational allogeneic BCMA-targeted CAR T cell therapy will be combined with nirogacestat, SpringWorks investigational gamma-secretase inhibitor in relapsedrefractory multiple myeloma. 